Pear Therapeutics
FDA-approved digital therapeutics don't matter if insurance companies refuse to pay for them.
Pear Therapeutics was a Healthcare/Digital Therapeutics startup founded in 2013 in USA. It raised $418M before collapsing in 2023 — 10 years of runway burned. IdeaProof's AI Failure Score: 68/100, driven by payer reimbursement failure. The shutdown affected employees, investors, and the broader Healthcare/Digital Therapeutics ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did Pear Therapeutics fail?
Pear Therapeutics failed in 2023 after 10 years of operation, losing $418M in raised capital. The root cause was payer reimbursement failure. Key lesson: FDA-approved digital therapeutics don't matter if insurance companies refuse to pay for them.
2013 → 2023
$418M
Healthcare/Digital Therapeutics
USA
IdeaProof AI Failure Score
What Happened: The Timeline
2013
Pear Therapeutics founded to create prescription digital treatments
2018
First FDA-cleared prescription app (reSET for substance abuse)
2021
Goes public via SPAC at $1.6B valuation
2022
Revenue only $12.4M, insurers refuse reimbursement
Apr 2023
Files for bankruptcy
Root Causes
Pear Therapeutics was a pioneer in FDA-approved prescription digital therapeutics (PDTs) — software-based treatments for substance abuse and insomnia. Despite being the first company to receive FDA clearance for prescription apps (reSET, Somryst), Pear couldn't get insurance companies to reimburse for digital treatments. Doctors were unfamiliar with prescribing apps. Revenue reached only $12.4M in 2022 while burning $30M+ per quarter. Pear filed for bankruptcy in April 2023, casting doubt on the entire digital therapeutics industry.
Sources & References
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank Pear Therapeutics.